home / stock / vaxx / vaxx news

VAXX News and Press, Vaxxinity Inc. From 08/09/23

Stock Information
Company Name: Vaxxinity Inc.
Stock Symbol: VAXX
Market: NASDAQ
Website: vaxxinity.com
Menu
VAXX VAXX Quote VAXX Short VAXX News VAXX Articles VAXX Message Board
Get VAXX Alerts

News, Short Squeeze, Breakout and More Instantly...
VAXX - Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. “Vaxxinity...
VAXX - Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of m...

VAXX - Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients

Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s ability to selectively target aggregated, toxic forms of neurodegenerative pro...

VAXX - BPTH and BIVI among healthcare gainers and losers

2023-06-26 10:08:32 ET Gainers: MoonLake Immunotherapeutics ( MLTX ) +69% . Chemomab Therapeutics ( CMMB ) +33% . Acelyrin ( SLRN ) +22% . ORIC Pharmaceuticals ( ORIC ) +15% . Losers: Avalo Therapeutics ( AVTX ) -85% . Fi...
VAXX - Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further clinical development. ...

VAXX - RARE, XP and KZR are among after hours movers

2023-06-05 17:18:34 ET Gainers: GitLab  ( GTLB ) +19% . HealthEquity ( HQY ) +6% . Kezar Life Sciences ( KZR ) +5% . Ultragenyx Pharmaceutical  ( RARE ) +4% . Vaxxinity ( VAXX ) +3% . Losers: Chijet Motor Compan...

VAXX - Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. &#...
VAXX - IDEX, LUNR and VAXX among mid-day movers

2023-04-26 13:36:28 ET Gainers: Crown ElectroKinetics ( CRKN ) +160% . EUDA Health Holdings Limited ( EUDA ) +50% . SAI.TECH Global Corporation SAI +34% . Intuitive Machines ( LUNR ) +30% . SOBR Safe SOBR +27% . TeraWulf WULF +22% ...

VAXX - Catalyst watch: Tesla deliveries, Walmart event and jobs report headline big week

2023-03-31 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

VAXX - Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress UB-313 to be Featured in Emerging Science Presentation at AAN Annual Meeting ...
Previous 10 Next 10